Chimeric OspA Vaccine Broadens Lyme Disease Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Lyme disease vaccines are limited in providing broad protection against various Borrelia species due to heterogeneity in OspA sequences, particularly in Europe where multiple genospecies are prevalent, necessitating a vaccine that can effectively immunize against multiple serotypes.
Innovation Solution
Development of chimeric OspA molecules that combine proximal and distal portions from different OspA serotypes to create stable, immunogenic proteins expressed in E. coli, forming a combination vaccine that protects against all six prevalent serotypes associated with Lyme disease in Europe and North America.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a monovalent OspA-based vaccine is used, then protection against a single serotype is achieved, but broad protection against multiple Borrelia genospecies is limited
Solution Approach 1:
The patent combines multiple OspA sequences from different serotypes into a single chimeric molecule. The chimeric OspA comprises an N-terminal region from one serotype and a C-terminal region from another serotype, creating a single protein that elicits antibodies against multiple serotypes simultaneously, thus resolving the contradiction between broad protection and vaccine complexity.
Solution Approach 2:
The chimeric OspA molecule is designed to serve multiple functions: it provides immunogenicity against multiple Borrelia serotypes (1, 2, 3, 4, 5, and 6) through a single vaccine component. This multi-functional design allows one vaccine composition to protect against diverse genospecies without requiring separate vaccines for each serotype.
2Stability of the object's composition
If lipidation of OspA is included, then molecular stability and protection without strong adjuvant are improved, but manufacturing complexity increases
Solution Approach 1:
The patent incorporates the lipid modification signal sequence (LipB leader sequence) at the N-terminus of the chimeric OspA construct before expression. This preliminary design element ensures that during recombinant protein production in E. coli, the OspA molecule is automatically lipidated and anchored to the outer membrane, providing stability and adjuvant properties without requiring post-production modification or strong adjuvants.
Solution Approach 2:
The chimeric OspA molecule performs self-lipidation through its built-in LipB leader sequence during the expression process. The protein automatically attaches to the bacterial outer membrane via fatty acid modification, eliminating the need for external adjuvants or complex post-processing steps, thus maintaining stability while simplifying the overall manufacturing process.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.